Table 3.
Univariable predictors of Pathobiological Determinants of Atherosclerosis in Youth (PDAY) risk scores among the 165 perinatally HIV-infected children in the study population at their most recent visit.
| Characteristic | Coronary Arteries PDAY Score | Abdominal Aorta PDAY Score | ||||||
|---|---|---|---|---|---|---|---|---|
| ≤ 0 (n=85) | ≥ 1 (n=80) | P* | C- statistic | 0 (n=126) | ≥1 (n=39) | P* | C-statistic | |
| Female, n (%) | 50 (59%) | 34 (43%) | 0.04 | 0.58 | NS | |||
| Current† HIV viral load, copies/mL, n (%) | 0.01 | 0.64 | ||||||
| ≤400 | NS | 68 (54%) | 30 (77%) | |||||
| 401–5,000 | 24 (19%) | 1 (3%) | ||||||
| >5,000 | 29 (23%) | 6 (15%) | ||||||
| Missing | 5 (4%) | 2 (5%) | ||||||
| Current† CDC category, n (%) | 0.05 | 0.60 | 0.06 | 0.61 | ||||
| N/A | 33 (39%) | 26 (33%) | 47 (37%) | 12 (31%) | ||||
| B | 33 (39%) | 22 (28%) | 46 (37%) | 9 (23%) | ||||
| C | 19 (22%) | 32 (40%) | 33 (26%) | 18 (46%) | ||||
| HAART | ||||||||
| Current† use, n (%) | NS | 105 (83%) | 38 (97%) | 0.03 | 0.57 | |||
| Boosted protease inhibitor | ||||||||
| Current† use, n (%) | 41 (48%) | 54 (68%) | 0.02 | 0.60 | 63 (50%) | 32 (82%) | <.01 | 0.66 |
| Ever use, n (%) | 56 (66%) | 66 (83%) | 0.02 | 0.58 | 88 (70%) | 34 (87%) | 0.04 | 0.59 |
| Cumulative duration of use, years, median (q1, q3) | 2.8 (0.0, 7.5) | 4.8 (1.3, 7.3) | 0.09 | 0.63 | 3.2 (0.0, 7.3) | 06.0 (4.5, 8.2) | <.01 | 0.71 |
| Lopinavir/ritonavir | ||||||||
| Current† use, n (%) | 18 (21%) | 30 (38%) | 0.03 | 0.58 | 26 (21%) | 22 (56%) | <.01 | 0.68 |
| Ever use, n (%) | 42 (49%) | 53 (66%) | 0.04 | 0.58 | 66 (52%) | 29 (74%) | 0.02 | 0.61 |
| Cumulative duration of use, years, median (q1, q3) | NS | 0.4 (0.0, 4.1) | 4.5 (0.0, 6.8) | <.01 | 0.66 | |||
| Abacavir | ||||||||
| Current† use, n (%) | NS | 29 (23%) | 17 (44%) | 0.02 | 0.60 | |||
| Lamivudine | ||||||||
| Current† use, n (%) | NS | 35 (28%) | 18 (46%) | 0.05 | 0.59 | |||
| Tenofovir disoproxil fumarate | ||||||||
| Ever use, n (%) | 58 (68%) | 42 (53%) | 0.06 | 0.58 | 81 (64%) | 19 (49%) | 0.09 | 0.58 |
*
Wilcoxon Test p-value for continuous variables, and Fisher’s Exact Test p-value for categorical variables.
†
Current defined as measurement at most recent visit.
CDC: Centers for Disease Control and Prevention (N/A: not/mildly symptomatic, B: moderately symptomatic, C: severely symptomatic (AIDS definition)), HAART: highly active antiretroviral therapy, NS: Not significant at p<0.10.